Exhibit 99.2
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0001.gif)
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0002.gif)
Alvin J. Glasky, Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer Rajesh C. Shrotriya, M.D. President, Chief Operating Officer Sam Gulko Senior Vice President of Finance, Chief Financial Officer |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0003.gif)
This presentation contains forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, the early stage of product development, preliminary unpublished research observations, the need for additional funding, the initiation and completion of clinical trials and dependence on third parties for clinical testing, manufacturing and marketing. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission. (c) 2002 NeoTherapeutics, Inc. All rights reserved. |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0004.gif)
2001 Annual Stockholders Meeting Where are we? Where are we going? How will we get there? |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0005.gif)
Sam Gulko Senior Vice President of Finance, Chief Financial Officer, Secretary and Treasurer Financial Update |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0006.gif)
Income Statement Data Fiscal year ended December 31: (in thousands except per share data) 2001 2000 1999 Revenues $ 41 $ -- $ -- Operating Expenses Research & Development $ 20,611 $ 38,767 $ 20,058 General and Administrative $ 7,580 $ 5,107 $ 5,924 Loss From Operations $ (28,150) $ (43,874) $ (25,982) Other Income (Expense) Principally Interest $ 315 $ (1,090) $ (8) Net Loss $ (27,835) $ (44,964) $ (25,990) Net Loss Per Share $ (1.46) $ (4.37) $ (3.68) Weighted Average Shares Outstanding 19,674,500 10,629,408 7,105,041 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0007.gif)
Income Statement Data Three months ended March 31: (in thousands except per share data) 2002 2001 2000 Revenues $ 20 $ -- $ -- Operating Expenses Research & Development $ 4,924 $ 3,807 $ 8,500 General and Administrative $ 1,479 $ 1,801 $ 955 Loss From Operations $ (6,383) $ (5,608) $ (9,455) Other Income (Expense) Principally Interest $ 77 $ 130 $ 124 Net Loss $ (6,306) $ (5,478) $ (9,331) Net Loss Per Share $ (0.26) $ (0.36) $ (1.02) Weighted Average Shares Outstanding 24,380,039 15,335,754 9,135,488 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0008.gif)
Balance Sheet (in thousands) 3/31/02 12/31/01 Cash and Marketable $ 5,812 $ 7,157 Securities Working Capital $ 2,128 $ 2,805 Total Assets $ 10,923 $ 12,825 Total Liabilities $ 4,560 $ 6,038 Minority Interest In Consolidated Subsidiaries $ - $ - Shareholder's Equity $ 6,362 $ 6,787 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0009.gif)
2002 Financings March, 2002 Common Stock with Warrants $ 6.2 million June, 2002 Common Stock with Warrants $ 1.7 million Total $ 7.9 million |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0010.gif)
Fully Diluted Common Shares June 14, 2001 Issued and Outstanding (50,000,000 Authorized) 33,647,434 Investor Warrants, Stock Options, etc. 8,553,340 Potential total fully diluted common shares 42,200,774 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0011.gif)
2000 2001 1Q-2002 Q2-2002 Q3-2002 Q4-2002 Burn Rate 4.1 2.3 2.1 1.6 0.9 0.9 Actual and Projected Burn Rate Burn Rate in $ Millions Projected Actual |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0012.gif)
Alvin J. Glasky, Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer Rajesh C. Shrotriya, M.D. President, Chief Operating Officer NeoTherapeutics' Technology Assets |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0013.gif)
NeoTherapeutics' Technology Assets Solid Technology Foundation Neurology Functional Genomics Generics (NeoJB) Oncology |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0014.gif)
Discovers and Develops Novel Patented Drugs Neurology Division NEUROLOGY DIVISION |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0015.gif)
Neurology Neotrofin(tm) Parkinson's Disease Spinal Cord Injury Chemotherapy-Induced Neuropathy |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0016.gif)
Neotrofin in Parkinson's Disease |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0017.gif)
Neotrofin in Parkinson's Disease Study Design Stable Parkinson's disease patients Double blind (24 Neotrofin, 6 Placebo) 2 weeks at 250 mg twice daily, then 2 weeks at 500 mg twice daily, then 8 weeks at 1,000 mg twice daily Follow-up for 4 weeks with no treatment |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0018.gif)
Neurology Slide 35 Neotrofin, Parkinson's Disease 082-2001-003 16.5 17 17.5 18 18.5 19 19.5 20 20.5 - -2 0 2 4 6 Weeks of Treatment Mean of UPDRS Pre-dose 250 mg 500 mg 1000 mg P=0.014 P=0.018 P=0.134 P=0.139 (N=20) 250 mgm BID for 2 weeks 500 mgm BID for 2 weeks 2/3 hrs. post 250 mgm 2/3 hrs. post 500 mgm 2/3 hrs. post 1,000 mgm A A ' B B' C C' |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0019.gif)
Neotrofin in Chemotherapy- Induced Neuropathy |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0020.gif)
30 32 34 36 38 40 42 44 46 48 50 Day 17 Control Vincristine Vincristine +Neotrofin 30mg Sensory Nerve Conduction Rate (m/sec) Data Source: AACR-NCI-EORTC Poster Neotrofin has neuroprotective and neuroregenerative effects on sensory nerve conduction responses in chemo- induced neuropathy model in rats * P<.05 Neotrofin(tm): Neuropathy Data Neurology |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0021.gif)
Neurology AIT-034 Dementia NEO-339 Attention Deficit Hyperactivity Disorder Mild Cognitive Impairment Neotrofin Parkinson's Disease Spinal Cord Injury Chemotherapy-Induced Neuropathy |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0022.gif)
Neurology NEO-339 in Attention Model |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0023.gif)
Neurology Neotrofin Parkinson's Disease Spinal Cord Injury Chemotherapy-Induced Neuropathy AIT-034 Dementia NEO-339 Attention Deficit Hyperactivity Disorder Mild Cognitive Impairment Antipsychotic Platform (AP Platform) Multiple Therapeutic Targets Schizophrenia Depression Parkinson's Disease Analgesia (Pain) |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0024.gif)
Importance of Antipsychotic Drugs Market size in 2001: Sales = $7.7 Billion Antipsychotics are 2% of all global pharmaceutical sales Market grew 30% in 2001 Olanzapine (Zyprexa) $ 3.1 Billion Clozapine (Clozaril) $ 1.0 Billion Risperidone (Risperdal) $ 1.8 Billion Others (Haldol, Seroquel, etc.) $ 1.8 Billion Source: IMS World Review |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0025.gif)
Neurology Antipsychotic Platform Efficacy is based upon a therapeutic balance between dopamine and serotonin neurotransmitter systems without effecting other receptors. |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0026.gif)
Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0027.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0028.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0029.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0030.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0031.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0032.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0033.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0034.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0035.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0036.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0037.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0038.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0039.gif)
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dopamine - D4.4 Serotonin - 5-HT1A Serotonin - 5-HT2A Sigma GABA Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0040.gif)
NEO-376 Does Not Produce Memory Disruption |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0041.gif)
Eight compounds evaluated Receptor binding profile different than marketed antipsychotics Minimal to no cognitive impairment Minimal side effects predicted Improved toxicology profile Antipsychotic Technology Platform |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0042.gif)
Antipsychotic Technology Platform These compounds represent a new generation of antipsychotic therapy |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0043.gif)
Functional Genomics Technology to Identify Targets for Drug Development NeoGene Technologies Slide 85 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0044.gif)
NeoGene Technologies, Inc. Two Pfizer alliances in 2001: $300,000 Milestone payments so far in 2002: $250,000 Recent publications 4 (1 pending) Highlights Slide 87 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0045.gif)
Manufacturing and Development of Patented and Generic Drugs and Over-the-counter Products NeoJB Slide 89 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0046.gif)
NeoJB Ciprofloxacin broad spectrum antimicrobial Ofloxacin broad spectrum antimicrobial Fluconazole antifungal Slide 91 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0047.gif)
NeoJB NeoJB is pursuing regulatory development of established products from India-based manufacturing sites Minimal financial resources are required at this time to further these efforts Slide 93 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0048.gif)
Development and Commercialization of Late-Stage Anti-Cancer Drugs NeoOncoRx Slide 95 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0049.gif)
Oncology Products Satraplatin Neoquin Elsamitrucin Slide 97 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0050.gif)
Elsamitrucin: Non-Hodgkin's Lymphoma Non-Hodgkin's Lymphoma 44,000 Phase 1 Phase 2 Phase 3 NDA New Cases/Year Source: UBS Warburg Estimated Market Size > $1 Billion Slide 99 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0051.gif)
Oncology Elsamitrucin Phase 1 Slide 101 Phase 2 Trials completed Colorectal Ovarian Breast Lung Non-Hodgkins Lymphoma 3 trials completed |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0052.gif)
Data Source: Bristol Myers Squibb Non-Hodgkin's Lymphoma Phase 2 study in 31 refractory patients 60% of patients had failed two or more prior treatment regimens 25% of patients showed an objective response Improved side effect profile Oncology Elsamitrucin Slide 103 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0053.gif)
Neoquin(tm) : Bladder Cancer Bladder Cancer 54,400 Phase 1 Phase 2 Phase 3 NDA New Cases/Year Source: Oncology, May 2000 Estimated Market Size > $300 Million Slide 105 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0054.gif)
Oncology Satraplatin Slide 107 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0055.gif)
Satraplatin : Advantages Outpatient Hospital Home Convenience Short IV infusion Prolonged IV infusion Oral Administration - - +++ $$ Satraplatin ++ ++ Cross-resistance In-vitro +++ +++ Activity / Efficacy $600+ million $200 million Sales Carboplatin Cisplatin Slide 109 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0056.gif)
Satraplatin: Prostate Cancer In a 50 patient phase 3 study, satraplatin shows a survival advantage over the current therapy Prednisone + Satraplatin Prednisone Data Source: Bristol Myers Squibb Slide 111 |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0057.gif)
NeoTherapeutics' Patents |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0058.gif)
NeoTherapeutics' U.S. Patent Status Issued Allowed Pending Total Neurology 9 1 16 26 Genomics 1 - 4 5 Oncology 6 - 1 7 (in-licensed) Corresponding foreign patents have been either issued or are pending |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0059.gif)
Summary of NeoTherapeutics' Technology Assets Neotrofin(tm) - Parkinson's Disease Neotrofin(tm) - Chemotherapy-Induced Neuropathy Neotrofin(tm) - Spinal Cord Injury AIT-034 - Dementia NEO-339 - Attention Deficit Hyperactivity Disorder NEO-339 - Mild Cognitive Impairment AP Platform - Schizophrenia AP Platform - Parkinson's Disease AP Platform - Depression AP Platform - Analgesia (Pain) Satraplatin - Prostate Cancer Satraplatin - Ovarian Cancer Satraplatin - Lung Cancer Neoquin(tm) - Bladder Cancer Neoquin(tm) - Radiation Sensitizer Elsamitrucin - Non-Hodgkins Lymphoma Neoquin Analogs Ciprofloxacin - Wide Spectrum Antimicribial Ofloxacin - Wide Spectrum Antimicribial Fluconazole - Antifungal OTC Products PcRP - Epilepsy ADP-Glucose - Cardiovascular Urotensin II - Movement Disorder Others - Cancer, Other Indications NeoJB NeoOncoRx Neurology NeoGene |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0060.gif)
2001 Annual Stockholders Meeting Where are we going? Where are we? |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0061.gif)
Where are we going? Complete ongoing low-cost studies Parkinson's Disease Chemotherapy-Induced Neuropathy Spinal Cord Injury Out-licensing Co-development (partnership) Satraplatin clinical development (upon receipt of capital) Initiate phase 3 clinical trial in prostate cancer Initiate three phase 2 clinical trials in Lung, Ovarian and Gastric Cancer, as a parallel registration strategy Strategies for Product Development |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0062.gif)
2001 Annual Stockholders Meeting How will we get there? Where are we going? Where are we? |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0063.gif)
What are our strategic plans going forward? Out-license products Co-development partnerships Cash financing through Investors Sale of divisions Merge the entire Company |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0064.gif)
Summary |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0065.gif)
It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0066.gif)
It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... There is real value in our technology and product platforms |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0067.gif)
It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... There is real value in our technology and product platforms Our challenge is to gain realization and recognition of this value in the marketplace |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0068.gif)
It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... There is real value in our technology and product platforms Our challenge is to gain realization and recognition of this value in the marketplace |
![](https://capedge.com/proxy/8-K/0000892569-02-001339/a82447a82447z0069.gif)